Department of Pediatrics, University of Catania, Regional Referral Centre for Inborn Errors Metabolism, Italy.
Clin Genet. 2011 Nov;80(5):452-8. doi: 10.1111/j.1399-0004.2010.01572.x. Epub 2010 Nov 11.
Krabbe leukodystrophy (KD) is a neurodegenerative lysosomal disorder caused by mutations in the galactocerebrosidase (GALC) gene. Different clinical forms are described based on the age at onset. In reported series, the early infantile form (EIKD) accounts for more than 90% of the cases. The rarer late onset forms (LOKD) become manifest later than 6 months up to the adult age. We report clinical, imaging, mutational analysis and geographic data in a large cohort of individuals with Krabbe disease examined over a 30-year period. Retrospective analyses of disease onset and long-term follow-up were conducted in 26 KD patients. Molecular analysis was performed in 12 patients and their families. Nine cases had EIKD, and 17 LOKD, accounting for two thirds of our series. No correlation was found between enzymatic activity, onset age and disease progression. Despite common geographical origin, only in a few cases could parental consanguinity be proven. The p.Gly41Ser mutation was associated with longer survival. A wide spectrum of LOKD is found despite similar genotype. Although current knowledge about onset age, residual enzyme activity and molecular analysis still fail to allow the identification of patient candidates for treatment, this information is valuable for long-term outcome prediction and could lead to reconsideration of inclusion criteria for bone marrow transplant (BMT) or other future therapeutic approaches.
克拉伯病(KD)是一种神经退行性溶酶体疾病,由半乳糖脑苷脂酶(GALC)基因突变引起。根据发病年龄描述了不同的临床形式。在报道的系列中,早婴型(EIKD)占病例的 90%以上。罕见的晚发型(LOKD)在 6 个月后至成年期才表现出来。我们报告了经过 30 年时间检查的大量克拉伯病患者的临床、影像学、突变分析和地理数据。对 26 名 KD 患者的疾病发病和长期随访进行了回顾性分析。对 12 名患者及其家属进行了分子分析。9 例为 EIKD,17 例为 LOKD,占我们系列的三分之二。酶活性、发病年龄和疾病进展之间没有相关性。尽管有共同的地理起源,但只有少数情况下可以证明父母近亲结婚。p.Gly41Ser 突变与更长的生存期相关。尽管基因型相似,但仍发现 LOKD 谱广泛。尽管目前关于发病年龄、残留酶活性和分子分析的知识仍不能确定治疗候选患者,但这些信息对于长期预后预测很有价值,并可能导致重新考虑骨髓移植(BMT)或其他未来治疗方法的纳入标准。